Stable cerebrospinal fluid neurogranin and β-site amyloid precursor protein cleaving enzyme 1 levels differentiate predementia Alzheimer’s disease patients

• Published in: Brain communications Vol. 4; no. 5; p. fcac244
• Main Authors: Kirsebom, Bjørn Eivind, Richter, Grit, Nordengen, Kaja, Aarsland, Dag, Bråthen, Geir, Tijms, Betty M, Visser, Pieter Jelle, Nilsson, Johanna, Selnes, Per, Kramberger, Milica G, Winblad, Bengt, Waterloo, Knut, Gísladóttir, Berglind, Blennow, Kaj, Fladby, Tormod
• Format: Journal Article
• Language: English
• Published: US Oxford University Press 2022
• Subjects: Original
• ISSN: 2632-1297; 2632-1297
• DOI: 10.1093/braincomms/fcac244

Cerebrospinal fluid (CSF) β-site amyloid precursor protein cleaving enzyme 1 (BACE1), neurogranin and the neurogranin/BACE1 ratio are proposed markers for Alzheimer’s disease. BACE1 is also a drug target. However, CSF levels may differ between early-stage amyloid plaque formation (A) and later stage...